Figure 3.
Changes in tumor size according to RECIST from pretreatment to during and after the commencement of each previous treatment. a. Lenvatinib. b. Ramucirumab. c. Sorafenib. d. Regorafenib.RECIST = response evaluation criteria in solid tumors.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.